<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713190</url>
  </required_header>
  <id_info>
    <org_study_id>EMPA-1</org_study_id>
    <nct_id>NCT03713190</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).</brief_title>
  <official_title>A Phase II,Randomized,Cross-over,Double-blind, Placebo- Controlled,Single Center Study of the Effect of Empagliflozin a SGLT-2 Inhibitor,on Endogenous Glucose Production and Plasma Glucagon Levels in Patients With ESRD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production
      and plasma glucagon levels in patients with end-stage renal disease (ESRD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of SGLT-2 inhibition on endogenous glucose production and plasma glucagon levels
      will be compared measured in patients with ESRD.The secondary endpoints are the mean
      difference in plasma glucose, insulin, c-peptide, FFA,GH, epinephrine, norepinephrine,
      cortisol and blood pressure during the last hour of the experiment between empagliflozin
      versus placebo administration in patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma Glucose level</measure>
    <time_frame>2 hours</time_frame>
    <description>Because of their mechanism of action, SGLT-2 inhibitor efficacy to reduce plasma glucose level is highly dependent upon renal function. With GFR decreasing, glucose tubular load will decrease and less glucose will be reabsorbed because of SGLT2-inhibition.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SGLT-2 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A substance without specific pharmacology principles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A substance without specific pharmacology principles</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females

          2. Age = 30-70 years

          3. BMI&amp;lt; 40 Kg/m 2 and stable weight (Â± 3 lbs) over the preceding three months

          4. Normal Glucose Tolerance (HbA1c &amp;gt; 4.5 % and &amp;lt; 5.7%) or Type 2 diabetes (HbA1c
             &amp;gt;5.7 % and &amp;lt;10.0%)

          5. End Stage Renal Disease (GFR &amp;lt;15 ml/min/1.73 m 2 or hemodialysis)

          6. Subjects are capable of giving informed consent

        Exclusion Criteria:

          1. Prednisone treatment

          2. Beta blocker or any medication that affects sympathetic/parasympathetic activity

          3. Known Empagliflozin Excipient Hypersensitivity

          4. Liver function enzymes higher more than two times the upper limit

          5. Ongoing urinary tract infection

          6. history of cancer of any type;

          7. cerebrovascular or symptomatic peripheral vascular disease;

          8. heart disease class III or IV NYHA;

          9. Type 1 Diabetes

         10. drug or alcohol abuse;

         11. life expectancy &amp;lt;3 yrs

         12. blood pressure &amp;gt;150/100 mmHg

         13. Donation of blood to a blood bank, blood transfusion, or participation in a clinical
             study requiring withdrawal of &amp;gt; 400 mL of blood during the 8 weeks prior to the
             enrollment visit and at least 8 weeks thereafter

         14. Women of child bearing potential who are unwilling or unable to use an acceptable
             method to avoid pregnancy for the entire study (estrogen and/or progesterone
             treatment)

         15. Patient with a history or current evidence of any condition, therapy, laboratory
             abnormality, or other circumstance which, in the opinion of the investigator or
             coordinator, might pose an unacceptable risk to the patient or interfere with trial
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Del prato</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Daniele</last_name>
    <phone>+3905099503</phone>
    <phone_ext>+3905099503</phone_ext>
    <email>segreteriadiabetologia@ao-pisa.toscana.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Del prato</last_name>
    <phone>+3905099503</phone>
    <phone_ext>+3905099503</phone_ext>
    <email>segreteriadiabetologia@ao-pisa.toscana.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism, University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Del Prato, MD</last_name>
      <phone>+39 050 995103</phone>
      <email>stefano.delprato@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Daniele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Prof. Stefano Del Prato</investigator_full_name>
    <investigator_title>Clinical Resercher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

